-
Mashup Score: 0Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer - npj Precision Oncology - 12 month(s) ago
Despite decades of study, the molecular mechanisms and selectivity of the biomolecular components of honeybee (Apis mellifera) venom as anticancer agents remain largely unknown. Here, we demonstrate that honeybee venom and its major component melittin potently induce cell death, particularly in the aggressive triple-negative and HER2-enriched breast cancer subtypes. Honeybee venom and melittin…
Source: NatureCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 5Breast Cancer - 12 month(s) ago
Breast Cancer
Source: ASCOCategories: Latest Headlines, Oncologists2Tweet-
RT @ASCO: Just issued: New ASCO and @Pathologists guideline update on #HER2 testing in #BreastCancer. Read more: https://t.co/19eZWWQj2V #b…
-
Just issued: New ASCO and @Pathologists guideline update on #HER2 testing in #BreastCancer. Read more: https://t.co/19eZWWQj2V #bcsm https://t.co/6UrDybIEti
-
-
Mashup Score: 0Genomic assay changes minds on HER2+ BC treatment - 1 year(s) ago
In a small study, 56% of oncologists revised plans after getting results of HER2DX tests.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#GenomicAssay changes minds on #HER2+ BC treatment 👉https://t.co/hQPSAs0BT3 @MDedgeHemOnc @Hsplete #Oncology https://t.co/HgVis4q7Ig
-
-
Mashup Score: 6HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers - 1 year(s) ago
HER2 is overexpressed in approximately 20% of esophagogastric cancer (EGC) cases. The addition of the anti-HER2 antibody, trastuzumab, to chemotherapy in 2010 was the first targeted treatment to demonstrate an improvement in survival. The aggressive nature and heterogeneous biology of EGC have posed a particular challenge and resulted in numerous negative trials without a change in standard of…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#HER2 Targeting in #EsophagogastricCancer: Redefining the Landscape and Breaking Barriers: https://t.co/rB57AsXxJX #GICSM Review by @Sam_Cytryn & @YJanjigianMD of @MSKCancerCenter https://t.co/pd9JzKbmoX
-
-
Mashup Score: 0CME / CE - Physicians' Education Resource - 1 year(s) ago
Physicians’ Education Resource – Newest Continuing Medical Education Live Events, Webcasts & Online Activities
Source: www.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New online course on current and emerging HER2-targeted therapies for the treatment of GI malignancies. Take the course: https://t.co/HAW2gaS4v7 #GIcancer #HER2 https://t.co/vLop6YOahJ
-
-
Mashup Score: 0Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
PUBLISHED: Clinical Genetic Features and #NeoadjuvantChemotherapy Response in #HER2-LowBreastCancers: A Retrospective, Multicenter Cohort Study. https://t.co/xpCbP160yy @McMastersKelly @SocSurgOnc https://t.co/LwyeGvqQdf
-
-
Mashup Score: 0
“It tells you that when two groups of people with different ancestry get the same treatment for the same subtype of cancer, they have a different response.”
Source: STATCategories: Healthcare Professionals, Latest HeadlinesTweet-
#Genetic differences in breast tumors may contribute to racial disparities https://t.co/Vy9n5QrszR via @statnews #HER2 #MAPK #PM101
-
-
Mashup Score: 3
Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the first and only positive Phase III study of a CDK4/6 inhibitor demonstrating consistent benefit in a broad population of patients with stage II and III HR+/HER2- early breast cancer (EBC) at risk of recurrence, including those with no nodal…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Great news in early #BreastCancer for patients with hormone receptor+/#HER2- disease: looking forward to seeing the absolute&relative benefit that would be key to justify an additional year of therapy as compared to current standard #OncoAlert #bcsm https://t.co/OK8YdcI2Mg https://t.co/Nvujd4ZS0t
-
-
Mashup Score: 0HER2 - 1 year(s) ago
Human epidermal growth factor receptor 2 (HER2) is one of four transmembrane tyrosine kinase receptor proteins in the epidermal growth factor receptor family. Normally expressed on epithelial cellular membranes of organs such as breast and skin, HER2 exists in other tissues, including gastrointestinal, respiratory, reproductive, urinary tract tissues, and more.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What do you know about #HER2? Visit our Biological Pathway Review for an overview on how HER2 works, plus expert insights and recent updates in the field. #BreastCancer https://t.co/nkI9AFf8Mg https://t.co/VJ77h2cYQj
-
-
Mashup Score: 6
Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2) alterations are found in approximately 2-5% of non-small cell lung cancers (NSCLCs); the majority are exon 20 insertion mutations. The efficacy and safety of poziotinib, an oral tyrosine kinase inhibitor, were assessed in treatment-naïve NSCLC patients whose tumors harbor HER2 exon 20 insertions.
Source: Journal of Thoracic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Phase II study of 1L poziotinib in #HER2 NSCLC @JTOonline. In 80pts (47 at 16mg qd, 33 at 8mg bid), RR 39%, DCR 73%, mDOR 5.7m, mPFS 5.6m. G3+ AEs include rash (45% qd, 39% bid), mucositis (21%, 15%), diarrhea (15%, 21%). RR 71% in G778_P780dupGSP. https://t.co/hM5IF7UwHb
-
#Honeybee #venom and #melittin suppress growth factor receptor activation in #HER2-enriched and triple-negative breast cancer | npj Precision Oncology https://t.co/mRdj5WpX1Z